Nuvation Bio Inc. - Common Stock (NUVB)

CUSIP: 67080N101

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 7 signals
Share change
+13,911,557
Put/Call ratio
4.6%
SEC-reported price per share
$5.68
Indexed holders
242
Value change
+$84,358,811
Number of buys
148
Open additional details 1 more signal available
Number of sells
77
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
339,200,672

Security key

67080N101

Report period

Q2 2026

Indexed institutions

242

Top holders

10

Ownership snapshot

Top reported holders of NUVB - Nuvation Bio Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
2/15
Latest evidence
31 Mar 2026
13F 13D/G 3/4/5 Lead comparable stake: 15% 13 rows are not safely comparable across share classes. 13D/G row: FMR LLC Showing 1-6 of 15 holder rows.

Quick read

FMR LLC leads the comparable SEC ownership view at 15%.

2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FMR LLC's linked filing trail.
Comparable ownership Top 2
FMR LLC 15%
BlackRock, Inc. 6.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FMR LLC
13F 13D/G
Company
15%
Reported 13D/G · 31 Mar 2025
$223,035,355
51,989,593 shares
— 31 Mar 2026
BlackRock, Inc.
13F 13D/G
Company
6.4%
Reported 13D/G · 30 Jun 2025
$107,680,605
25,100,374 shares
— 31 Mar 2026
Omega Fund V, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$114,561,104
20,457,340 shares
— 05 Apr 2022
David Hung
3/4/5
PRESIDENT AND CEO, Director, 10%+ Owner
—
mixed-class rows
$105,935,243
61,276,066 shares
mixed-class rows
— 27 Feb 2026
Decheng Capital LLC
13F
Company
13F
—
denominator unverified
$111,344,543
25,954,439 shares
— 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$49,876,389
11,626,198 shares
— 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
242
Shares
233,386,890
Indexed holders
242
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 indexed holders
230
Q2 2026 indexed holders
242
Indexed holder difference
12
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .